Page last updated: 2024-10-30

mesalamine and Sicca Syndrome

mesalamine has been researched along with Sicca Syndrome in 2 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bar Yehuda, S1
Axlerod, R1
Toker, O1
Zigman, N1
Goren, I1
Mourad, V1
Lederman, N1
Cohen, N1
Matz, E1
Dushnitzky, D1
Gavish, M1
Borovsky, N1
Schwarts, D1
Dotan, I1
Turner, D1
Qanneta, R1
García Pardo, G1
Florit Serra, L1

Other Studies

2 other studies available for mesalamine and Sicca Syndrome

ArticleYear
The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN.
    Journal of Crohn's & colitis, 2019, Mar-26, Volume: 13, Issue:3

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Biological Products; Case

2019
Acute pleuropericarditis in a patient with primary Sjögren's syndrome and quiescent ulcerative colitis in longstanding 5-aminosalicylic acid therapy.
    Journal of Crohn's & colitis, 2013, Volume: 7, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine; Middle Age

2013